Financial Performance - Revenue increased by RMB 161.4 million or 2.7% to RMB 6,143.1 million compared to the year ended December 31, 2022[2]. - EBITDA rose by RMB 264.6 million or 14.6% to RMB 2,077.4 million compared to the previous year[2]. - Gross profit increased by RMB 63.7 million or 1.5% to RMB 4,204.2 million, with a gross profit margin of 68.4%[2]. - Profit before tax increased by RMB 30.3 million or 4.5% to RMB 700.1 million compared to the year ended December 31, 2022[2]. - Net profit attributable to shareholders decreased to RMB 532.6 million, a decline of RMB 72.2 million compared to the previous year[2]. - Basic earnings per share decreased to RMB 14.29 from RMB 17.38 in the previous year[2]. - Total revenue for the year ended December 31, 2023, was RMB 6,143,078 thousand, an increase from RMB 5,981,656 thousand in 2022, representing a growth of approximately 2.7%[23][26]. - The pre-tax profit for the year ended December 31, 2023, was RMB 700,100 thousand, compared to RMB 669,762 thousand in 2022, indicating an increase of about 4.5%[21][23]. Assets and Liabilities - Total non-current assets increased to RMB 14,787.4 million from RMB 13,463.8 million in the previous year[6]. - Current assets totaled RMB 10,703.3 million, slightly down from RMB 10,785.8 million in the previous year[6]. - Cash and cash equivalents increased to RMB 3,238.9 million from RMB 2,323.7 million in the previous year[6]. - As of December 31, 2023, total current liabilities decreased to RMB 8,137,807 thousand from RMB 9,487,203 thousand in 2022, representing a reduction of approximately 14.3%[7]. - The net value of current assets increased significantly to RMB 2,565,475 thousand in 2023, compared to RMB 1,298,610 thousand in 2022, marking a growth of approximately 97.6%[7]. - Total assets minus current liabilities rose to RMB 17,352,908 thousand in 2023, up from RMB 14,762,422 thousand in 2022, indicating an increase of about 17.7%[7]. - The total equity attributable to the parent company increased to RMB 12,531,185 thousand in 2023 from RMB 10,175,954 thousand in 2022, reflecting a growth of approximately 23.2%[8]. - The company’s total non-current liabilities amounted to RMB 3,824,414 thousand in 2023, slightly up from RMB 3,720,700 thousand in 2022, indicating a marginal increase of about 2.8%[7]. Revenue Breakdown - The segment revenue from tumor drugs was RMB 5,627,352 thousand for 2023, while the revenue from cardiovascular system drugs was RMB 1,687,359 thousand[22]. - Revenue from sales products amounted to RMB 5,627,352 thousand in 2023, compared to RMB 5,059,298 thousand in 2022, reflecting an increase of about 11.2%[25][26]. - The revenue from R&D services was RMB 81,550 thousand in 2023, up from RMB 86,689 thousand in 2022, indicating a decrease of approximately 6.5%[25][26]. - The total revenue from the Chinese mainland market was RMB 5,029,604 thousand in 2023, a slight decrease from RMB 5,031,164 thousand in 2022, reflecting a marginal decline of approximately 0.03%[25][26]. Expenses and Costs - Administrative expenses for the year were RMB 643,967 thousand, up from RMB 582,870 thousand in 2022, reflecting an increase of approximately 10.5%[21][23]. - The cost of goods sold for 2023 was RMB 1,866,830,000, compared to RMB 1,762,326,000 in 2022, indicating an increase of about 5.9%[30]. - Research and development expenses decreased to RMB 586,157,000 in 2023 from RMB 857,337,000 in 2022, a reduction of approximately 31.6%[30]. - Total financial costs rose to RMB 675,454,000 in 2023, up from RMB 471,755,000 in 2022, marking an increase of about 43.2%[32]. - The total tax expense for the year was RMB 161,023,000, significantly higher than RMB 86,466,000 in 2022, reflecting an increase of approximately 86.2%[35]. Dividends and Share Capital - The board does not recommend the payment of a dividend for the year ended December 31, 2023[2]. - The company did not declare or propose any interim or final dividends for the year ending December 31, 2023, consistent with 2022[38]. - Basic earnings per share for the year were calculated based on 3,728,362,856 shares, an increase from 3,480,852,775 shares in 2022[38]. - The issued share capital rose to RMB 486,107 thousand in 2023, up from RMB 456,953 thousand in 2022, which is an increase of about 6.4%[8]. Research and Development - The R&D team consists of 931 employees, including 86 PhDs and 467 Master's degree holders, as of December 31, 2023[70]. - The company holds 271 patents in China and 508 patents overseas, with 61 and 123 patents pending, respectively[70]. - The company is actively engaged in strategic development in cell therapy and gene therapy[54]. - The company has over 30 domestic and more than 10 international products in the research pipeline[54]. Market and Product Development - The company has established eight production bases globally and maintains a GMP quality management system[54]. - The company has initiated multiple global collaborations, including a partnership with Abacus Medicine Pharma Services for the exclusive distribution of Lurbinectedin in Hong Kong[91]. - The company signed an agreement with Zhengda Qingdao for the exclusive sales rights of Dushudan injection in mainland China in January 2023[91]. - The company completed strategic cooperation with Baijie Shenzhou for the commercialization of its innovative formulation, Goserelin microspheres, in mainland China in July 2023[91]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]. - The group expects existing products to achieve stable growth, with new products approved in the past three years anticipated to ramp up quickly[93]. - The innovative formulation of Baitowei for prostate and breast cancer treatment has been approved for commercialization in China, with a significant market potential estimated at RMB 9.72 billion[94].
绿叶制药(02186) - 2023 - 年度业绩